ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 64 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,604 | +69.0% | 16,161 | -56.5% | 0.00% | – |
| Q2 2023 | $12,192 | -21.3% | 37,110 | -1.3% | 0.00% | – |
| Q1 2023 | $15,486 | -3.2% | 37,609 | +19.9% | 0.00% | – |
| Q4 2022 | $16,000 | -33.3% | 31,359 | +0.6% | 0.00% | – |
| Q3 2022 | $24,000 | -36.8% | 31,159 | -4.0% | 0.00% | – |
| Q2 2022 | $38,000 | -72.9% | 32,459 | +99.2% | 0.00% | – |
| Q1 2022 | $140,000 | +288.9% | 16,294 | +28.7% | 0.00% | – |
| Q4 2021 | $36,000 | -21.7% | 12,662 | +16.1% | 0.00% | – |
| Q3 2021 | $46,000 | -22.0% | 10,902 | -4.0% | 0.00% | – |
| Q2 2021 | $59,000 | +7.3% | 11,352 | -4.8% | 0.00% | – |
| Q1 2021 | $55,000 | +52.8% | 11,925 | +5.2% | 0.00% | – |
| Q4 2020 | $36,000 | -47.8% | 11,335 | -46.4% | 0.00% | – |
| Q3 2020 | $69,000 | -36.1% | 21,135 | -34.3% | 0.00% | – |
| Q2 2020 | $108,000 | -8.5% | 32,155 | +4.4% | 0.00% | – |
| Q1 2020 | $118,000 | – | 30,786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |